Executive record

John R. Pinion II

Chief Quality Officer and Executive Vice President of Translational Sciences at Ultragenyx Pharmaceutical Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:john-r-pinion-iiVersion: public-0As of: 2026-09-29

Not yet claimed6 published Claims2 sources
  • Executive

Key Claims

Biography

Mr. Pinion has served as Chief Quality Officer and Executive Vice President of Translational Sciences since September 2017, with prior roles at Genentech from 2005 to 2015 including SVP and Global Head of Quality and Compliance for Roche/Genentech Pharma Technical Operations. He holds a B.S. in Mechanical Engineering from the University of West Virginia.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. Current · dates not publishedChief Quality Officer and Executive Vice President of Translational Sciences · Ultragenyx Pharmaceutical Inc.
  2. 2026 to end not publishedExecutive title: Chief Quality Officer and Executive Vice President of Translational Sciences · Organization not publishedRARE DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. RARE DEF 14A executive officers

    sec filing · Source published: Mar 27, 2026 · Retrieved: May 5, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Executive company: Executive at Ultragenyx Pharmaceutical Inc. · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Chief Quality Officer and Executive Vice President of Translational Sciences · Claim reviewed: May 5, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 5, 2026

  2. Open source

    sec def 14a · Source published: Mar 27, 2026 · Retrieved: Sep 12, 2026

    Supports 1 claim
    • Professional Role: Chief Quality Officer and Executive Vice President of Translational Sciences at Ultragenyx Pharmaceutical Inc. · Claim reviewed: Sep 12, 2026